三氧化二砷联合沙利度胺对骨髓增生异常综合征的调节作用

摘要

Objective To explore the regulatory effects of arsenic trioxide combined with thalidomide on myelodysplastic syndrome (MDS).Methods Forty-six patients with MDS were divided into two groups randomly,23 cases in each group.The treatment group was treated with arsenic trioxide combined with thalidomide,while the control group with arsenic trioxide alone.Two months later,the total therapeutic effects of 2 groups were assessed,and hemoglobin (Hb),absolute of neutrocytes (ANC),blood platelet count (PLT),proportion of original cells in bone marrow and adverse reaction of 2 groups were compared.Results The total effectiveness rate in the treatment group was obviously higher than that in the control group.The improving condition of Hb,ANC,PLT and proportion of original cells in bone marrow in the treatment group were obviously superior to those in the control group.The incidence of adverse reactions of 2 groups showed no significant difference.Conclusion Compared with the usage of arsenic trioxide alone,its combined with thalidomide can significantly improve trilineage blood cells,decrease the proportion of original cells in bone marrow,and improve the short-term therapeutic effect,without more adverse reactions.%目的 探讨三氧化二砷联合沙利度胺对骨髓增生异常综合征(MDS)的调节作用.方法 将46例MDS患者随机分为2组,每组23例.治疗组给予三氧化二砷及沙利度胺,对照组仅给予三氧化二砷.治疗2个月后评估2组总体疗效,比较血红蛋白(Hb)、中性粒细胞绝对值(ANC)、血小板计数(PLT)、骨髓原始细胞比例及不良反应的差异.结果 治疗组总有效率显著高于对照组.治疗组Hb、ANC、PLT水平及骨髓原始细胞比例的改善程度均显著大于对照组.2组不良反应发生率无显著差异.结论 与单独应用三氧化二砷相比,三氧化二砷联合沙利度胺可显著改善MDS患者三系血细胞,降低骨髓原始细胞比例,提高近期疗效,且不增加不良反应.